Healthcare
KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists
Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, today announced results published in the peer-reviewed medical journal Diabetes, Obesity and Metabolism from its most comprehensive real-world evidence (RWE) study to date for its FDA-approved kidneyintelX.dkd test.
About this update from Renalytix Plc
Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk-stratified improvements in kidney function, increases in guideline-directed therapy uptake, and - for the first time - measurable reduction in individual patient risk trajectories over 24 months NEW YORK, June 30, 2026 /PRNewswire/ -- Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, today announced results published in the peer-reviewed medical journal Diabetes, Obesity and Metabolism from its most comprehensive real-world evidence (RWE) study to date for its FDA-approved kidneyintelX.dkd test. Spanning 2,470 patients with type 2 diabetes and early-stage chronic kidney disease (CKD) across two major U.S. health systems, Mount Sinai Health System in New York and Wake Forest/Atrium Health in North Carolina, the IRB-approved prospective study reveals that kidneyintelX.dkd not only transforms how clinicians assess risk but changes the course of disease over a full two year period, a first for any kidney prognostic tool. "These two-year data provide the clearest real-world picture yet of what risk stratification can do when applied consistently at scale in two large health systems. What we see is that a structured, biomarker-guided approach to prescribing translates into targeted therapy decisions — higher-risk patients receiving more intensive treatment, and lower-risk patients largely spared unnecessary escalation. That is what precision medicine is supposed to look like in practice." - Dr David Lam, Co-Principal InvestigatorEndocrinologist with the Mount Sinai Health System A LEAP BEYOND PRIOR EVIDENCEThe KidneyIntelX real-world evidence program has evolved from the 6- to 12- to 24-month time periods, demonstrating sustainable clinical improvements tied to how the test's risk stratification successfully informs guideline-directed medical treatment (GDMT).